Health Care · Services-Commercial Physical & Biological Research

MXCT MAXCYTE, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 128709858 filings
Russell 2000

MXCT at a glance

MAXCYTE, INC. (MXCT, SEC CIK 1287098) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), MAXCYTE, INC. (MXCT) reported revenue of $21.0 million (down 5.7% from FY2024) and a net loss of $44.6 million. Diluted EPS was -$0.42.
  • As of September 30, 2026, 19 institutional investment managers tracked by SignalX reported holding MAXCYTE, INC. (MXCT) shares worth $22.7 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Masoud Maher on November 17, 2026 of 100,000 shares at $1.21 per share.
  • In the last 90 days, MXCT insiders reported 1 open-market purchase ($121K) and 0 open-market sales ($0) on Form 4, a net purchase of $121K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$21.0M
−5.7% vs prior year
Insiders · 90 days
1 buy · 0 sells
Net +$121K
13F holders
19 funds
$22.7M · −1 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02 · Item 1.01 · Item 3.02 · Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added risk: proposed Akron acquisition may fail or be delayed, triggering unrecoverable transaction costs and potential stock-price decline
  • Acquisition consideration: $105.0 million cash, 20,639,733 shares, and $20.0 million guaranteed deferred payments due January 2028 and January 2029
  • Regulatory and compliance risk: Akron integration requires cGMP compliance and public-company financial controls
  • Operational risk: limited experience with Akron’s reagent business may hinder integration, customer retention, and cross-selling
  • Financial risk: proposed debt includes $20.0 million term borrowing and $2.0 million revolver borrowing at closing, with variable SOFR-based interest

Management Discussion & Analysis

  • Revenue $10.2M, up 49% YoY from $6.8M, driven by SPL milestones and royalties
  • Gross margin 83% vs 77% YoY, supported by higher-margin milestone and royalty revenue
  • Best line: instrument revenue $2.8M, up 102%; weakest: Assay Service revenue down 83%
  • Operating cash outflow $18.3M for nine months, versus $31.7M YoY; $5.5M stock repurchases
  • Outlook: near-term operating losses, revenue volatility, and proposed Akron acquisition requiring $105.0M cash plus $22.0M initial debt draw

AI summary of the MXCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced November 10, 2026
  • Press release contains the financial results and accompanying investor-relevant disclosures

Item 1.01: Entry into a Material Definitive Agreement

  • MaxCyte acquiring Akron BioProducts for $105.0M cash, 20,639,733 shares, and $20.0M deferred cash
  • Deferred payments split into $10.0M due in 2028 and $10.0M due in 2029, adding future cash obligations

Item 3.02: Unregistered Sales of Equity Securities

  • 20,639,733 MXCT shares to be issued to sellers as stock consideration at transaction closing
  • Private placement under Securities Act Section 4(a)(2), avoiding public registration

Item 7.01: Regulation FD Disclosure

  • Acquisition announcement, investor presentation, and corporate presentation released November 10, 2026
  • Closing depends on Hart-Scott-Rodino waiting-period expiration or termination

Item EX-99.2: Item EX-99.2

  • Acquisition of Akron Bio for $151.8M, expected to close before year-end 2026
  • Akron projected 2026 revenue $28M and EBITDA $7M-$8M, adding recurring consumables revenue

Item EX-99.4: Item EX-99.4

  • Corporate presentation highlights 3Q26 core revenue $8.157M, up 27% year over year
  • YTD 2026 total revenue $27.074M, up 5%, while core revenue declined 9% to $20.877M

Item EX-99.3: Item EX-99.3

  • Acquisition consideration ~$151.8M: $105.0M cash, 20.6M shares, and $20.0M deferred payments in 2028–2029
  • Akron adds $28M expected 2026 revenue, $7M–$8M EBITDA, and positive cash flow to roughly double MaxCyte’s revenue base

Item EX-99.1: Item EX-99.1

  • Q3 revenue $10.2M, up 49%, with core revenue $8.2M up 27% and SPL revenue $2.0M
  • Gross margin improved to 83% from 77%, while operating expenses fell to $14.5M from $19.4M
Filed Oct 14, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Preliminary unaudited revenue results for quarter ended September 30, 2026
  • Full-year 2026 revenue guidance increased, signaling stronger expected business performance

Item EX-99.1: Item EX-99.1

  • Preliminary Q3 core revenue $8.1M, up 26% year over year, signaling resumed growth
  • SPL program revenue exceeded $1.0M, including a $1.0M milestone payment
Filed Aug 12, 2026Full analysis →

Item EX-99.1#2: Item EX-99.1#2

  • Corporate presentation updates investors on MaxCyte’s platform, customer pipeline, financial profile, and growth strategy as of August 2026
  • Core revenue $12.7M, down 23% year-to-date, signaling continued weakness despite SPL-related revenue growth of 71% to $4.2M

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation posted August 12, 2026 for investor communications and conferences
  • Exhibit 99.2 contains management’s latest corporate messaging and strategy context

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 announced August 12, 2026
  • Full financial results and management commentary furnished in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $7.3M, down 15% YoY; core revenue $6.5M, down 21%, signaling continued operating softness
  • SPL revenue rose to $0.8M from $0.3M, driven by royalties up 150% to $0.8M

AI summaries of MXCT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MXCT

Don't miss the next MXCT filing

  • Alerts as it files. A push when MXCT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MXCT, by share count.
  • Ask anything. An AI agent that reads every MXCT filing and answers with sources.

MXCT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Masoud MaherBuyNov 17, 2026$1.21
Collins CynthiaAJun 17, 2026-
Hemrajani RekhaAJun 17, 2026-
Al-Wakeel Yasir B.AJun 17, 2026-
Al-Wakeel Yasir B.AJun 17, 2026-
Hemrajani RekhaAJun 17, 2026-
DOUGLAS RICHARDAJun 17, 2026-
Brooke William WAJun 17, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$22.2M$21.0M
Gross Profit-$31.5M$26.8M
Operating Income--$51.2M-$51.9M
Net Income--$41.1M-$44.6M
Gross Margin-141.9%127.9%
Op. Margin--230.5%-247.6%
Net Margin--184.8%-213.0%
Balance Sheet
Total Assets$268.3M$239.5M$202.5M
Equity-$206.3M$171.5M
ROE--19.9%-26.0%
Per Share
EPS-$-0.39$-0.42
Cash Flow
Operating CF--$27.6M-$34.4M
CapEx$3.7M$1.7M$1.8M

Source: XBRL data in MAXCYTE, INC. (MXCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MXCT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MXCT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202619$22.7M
Q2 202620$26.0M
Q1 202625$19.4M
Q4 202523$45.3M
Q3 202523$48.3M
Q2 202524$71.8M
Q1 202521$63.5M
Q4 202419$72.2M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 174 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MXCT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
8-KNov 10, 2026Analysis-
10-QNov 10, 2026Analysis
8-KOct 14, 2026Analysis-
10-QAug 13, 2026Analysis
8-KAug 12, 2026Analysis-
SC 13DAug 4, 2026-
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
8-KJun 17, 2026Analysis-
8-KJun 16, 2026Analysis-
SC 13DMay 14, 2026-
10-QMay 13, 2026Analysis
8-KMay 12, 2026Analysis
4Apr 17, 2026--
4Apr 10, 2026--
4Mar 31, 2026--
8-KMar 27, 2026--
10-KMar 25, 2026-

Related Health Care companies

All Health Care →

MXCT SEC filings: frequently asked questions

Are MXCT insiders buying or selling?

In the last 90 days, MAXCYTE, INC. (MXCT) officers, directors and 10% owners reported 1 open-market purchase worth $120,780 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MXCT stock?

As of September 30, 2026, the largest MAXCYTE, INC. (MXCT) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($4.5 million), Morgan Stanley ($4.5 million), BlackRock ($3.4 million), Two Sigma Investments ($2.7 million), Renaissance Technologies LLC ($2.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MXCT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), MAXCYTE, INC. (MXCT) reported revenue of $21.0 million (down 5.7% from FY2024) and a net loss of $44.6 million. Diluted EPS was -$0.42. The figures come from the XBRL data in the 10-K.

What did MXCT report in its latest 8-K?

MAXCYTE, INC. (MXCT) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities) and Item 7.01 (Regulation FD Disclosure). Q3 2026 results for quarter ended September 30, 2026 announced November 10, 2026.

What are the latest MXCT SEC filings?

MAXCYTE, INC. (MXCT) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 18, 2026.

What is MXCT's SEC CIK number?

MAXCYTE, INC. (MXCT)'s SEC Central Index Key (CIK) is 1287098. EDGAR lists every MXCT filing under that number.

Ask anything about MXCT

The research agent reads MXCT's filings, financials, insider trades and 13F holders, then answers with sources.